Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

ABSTRACT: Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor an

SUBMITTER: Krantz BA 

PROVIDER: S-EPMC5955785 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature